Fertility preservation in pediatric, adolescent and young adult female cancer patients

Pediatric Endocrinology Reviews

Volumn 10, Issue 1, 2012, Pages 174-187

  Ayensu Coker, Leslie ^a   Bauman, Dvora ^b   Lindheim, Steven R ^c   Breech, Lesley ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BIKUR CHOLIM HOSPITAL   (Israel)

^c UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Adolescent and young adult (AYA); Cancer; Chemotherapy; Fertility preservation; Infertility; Oncofertility; Oncology; Ovarian failure; Ovarian reserve; Ovarian reserve testing; Pediatric and adolescent gynecology; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; GONADORELIN;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; COUNSELING; CRYOPRESERVATION; DRUG EFFECT; FEMALE; FERTILITY; FERTILITY PRESERVATION; GYNECOLOGIC CANCER; GYNECOLOGICAL EXAMINATION; HUMAN; OVARIAN RESERVE; OVARIAN RESERVE TESTING; OVARY DEVELOPMENT; OVARY FOLLICLE ATRESIA; REVIEW; THERAPY EFFECT; ADOLESCENT; ADULT; CHILD; FEMALE INFERTILITY; METHODOLOGY; NEOPLASM; OOCYTE; OVARY; POSTOPERATIVE COMPLICATION; PSYCHOLOGICAL ASPECT; RADIOTHERAPY; REPRODUCTIVE PROCEDURE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; COUNSELING; CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; OOCYTES; OVARY; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY;

MLCS; MLOWN;

EID: 84875615211     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. American Cancer Society. Cancer Facts 7 Figures 2010. Atlanta: American Cancer Society, 2010.
2. Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009; 101 (7):533-6. Epub 2009/03/26.
3. Sauvat F, Binart N, Poirot C, Sarnacki S. Preserving fertility in prepubertal children. Horm Res. 2009; 71 Suppl 1:82-6. Epub 2009/01/30.
4. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. Jama. 2007; 297 (24):2705-15. Epub 2007/06/28.
5. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001 ; 7 (6):535-43 Epub2001/12/01.
6. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999; 5 (5):483- 92. Epub 1999/12/03.
7. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Lossl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010; 94 (1):156-66. Epub 2009/04/04.
8. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PloS one. 2010; 5 (1):e8772. Epub 2010/01/30.
9. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer. 1999; 86 (4):697-709. Epub 1999/08/10.
10. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000; 21 (2):200-14. Epub 2000/04/27.
11. Wallberg KA, Keros V, Hovatta O. Clinical aspects of fertility preservation in female patients. Pediatr Blood Cancer. 2009; 53 (2):254-60. Epub 2009/04/03.
12. Morice P, Camatte S, Wicart-Poque F, Atallah D, Rouzier R, Pautier P, et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update. 2003:9 (2):185- 92. Epub 2003/05/20.
13. Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol. 2000:95 (4):541-7. Epub 2000/03/22.
14. Rodriguez-Wallberg KA, Keros V, Hovatta O. Clinical Aspects of Fertility Preservation in Female Patients. Pediatr Blood Cancer. 2009; 53:254-60.
15. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010; 53 (4):727-39. Epub 2010/11/05.
16. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24 (18):2917-31. Epub 2006/05/03.
17. Adriaens I, Smitz J, Jacquet P. The current knowledge on radiosensitivity of ovarian follicle development stages. Hum Reprod Update. 2009; 15 (3):359-77. Epub 2009/01/20.
18. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005; 62 (3):738-44. Epub 2005/06/07.
19. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol. 1999; 33 (1):2-8. Epub 1999/07/13.
20. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003; 18 (1): 117-21. Epub 2003/01/15.
21. Wallace WH, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: the radiosensitivity of the human oocyte. The British journal of radiology 1989; 62 (743):995-8. Epub 1989/11/01.
22. Bianchi M. The Ovary. In: Potten CS, Hendry, J. H., editor. Cytotoxic Insult to Tissue: Effects on Cell Lineages. 1st ed. Edinburgh, UK- Churchill Livingstone; 1983. p. 308-28.
23. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003; 18 (11):2368-74 EDub 2003/10/31.
24. Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr. 2005 (34):64-8. Epub 2005/03/24.
25. Larsen EC, Schmiegelow K, Rechnitzer C, Loft A, Muller J, Andersen AN. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta obstetricia et gynecologica Scandinavica. 2004; 83 (1):96-102. Epub 2003/12/18.
26. Green DM, Hall B, Zevon MA. Pregnancy outcome after treatment for acute lymphoblastic leukemia during childhood or adolescence. Cancer. 1989; 64 (11):2335-9. Epub 1989/12/01.
27. Duncan FE, Jozefik JK, Kim AM, Hirshfeld-Cytron J, Woodruff TK. The Gynecologist Has a Unique Role in Providing Oncofertility Care to Young Cancer Patients. US obstetrics Et gynaecology. 2011 ; 6 (1):24-34. Epub 2011/09/20.
28. Gracia CR, Chang J, Kondapatli L, Prewitt M, Carlson CA, Mattei P, et al. Ovarian tissue cryopreservation for fertility preservation in cancer patients: Successful establishment and feasibility of a multidisciplinary collaboration. Journal of assisted reproduction and genetics. 2012; 29 (6):495-502. Epub 2012/04/03.
29. Weintraub M, Gross E, Kadari A, Ravitsky V, Safran A, Laufer N, Revel A. Should ovarian cryopreservation be offered to girts with cancer. Pediatr Blood Cancer. 2007; 48 (1):4-9. Epub 2006/07/11.
30. ASRM Ethics Committee. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005; 83 (6):1622-8. Epub 2005/06/14.
31. Nieman CL, Kinahan KE, Yount SE, Rosenbloom SK, Yost KJ, Hahn EA, et al. Fertility preservation and adolescent cancer patients: lessons from adult survivors of childhood cancer and their parents. Cancer treatment and research. 2007; 138:201-17. Epub 2007/12/18.
32. Burns KC, Boudreau C, Panepinto JA. Attitudes regarding fertility preservation in female adolescent cancer patients. J Pediatr Hematol Oncol. 2006; 28 (6):350-4. Epub 2006/06/24.
33. Gracia CR, Ginsberg JP. Fertility Risk in Pediatric and Adolescent Cancers. In: Woodruff TSK, editor. Oncofertility preservation for cancer survivors. New York: Springer Verlag; 2007. p. 57-68.
34. Kim SS. Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril. 2006; 85 (1):1-11. Epub 2006/01/18.
35. Kuleshova LL, Lopata A. Vitrification can be more favorable than slow cooling. Fertil Steril. 2002; 78 (3):449-54. Epub 2002/09/07.
36. Noyes N, Knopman J, Labella P, McCaffrey C, Clark-Williams M, Grifo J. Oocyte cryopreservation outcomes including pre-cryopreservation and post-thaw meiotic spindle evaluation following slow cooling and vitrification of human oocytes. Fertil Steril. 2010; 94 (6):2078-82. Epub 2010/03/02.
37. Gunby J, Bissonnette F, Librach C, Cowan L. Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register. Fertil Steril. 2009; 91 (5):1721-30. Epub 2008/04/22.
38. Donnez J, Silber S, Andersen CY, Demeestere I, Piver P, Meirow D, et al. Children born after autotransplantation of cryopreserved ovarian tissue, a review of 13 live births. Ann Med. 2011; 43 (6):437-50. Epub 2011/01/14.
39. Silber S, Kagawa N, Kuwayama M, Gosden R. Duration of fertility after fresh and frozen ovary transplantation. Fertil Steril. 2010; 94 (6):2191-6. Epub 2010/02/23.
40. Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005; 353 (3):318-21. Epub 2005/06/29.
41. Arav A, Gavish Z, Elami A, Natan Y, Revel A, Silber S, Gosden RG, Patrizio P. Ovarian function 6 years after cryopreservation and transplantation of whole sheep ovaries. Reprod Biomed Online. 2010; 20 (1):48-52. Epub 2010/02/18.
42. Woodruff TK. The Oncofertility Consortium - addressing fertility in young people with cancer. Nature reviews Clinical oncology. 2010; 7 (8):466-75. Epub 2010/05/26.
43. Smitz J, Dolmans MM, Donnez J, Fortune JE, Hovatta O, Jewgenow K, et al. Current achievements and future research directions in ovarian tissue culture, In vitro follicle development and transplantation: implications for fertility preservation. Hum Reprod Update. 2010; 16 (4):395-414. Epub 2010/02/04.
44. Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril. 2000; 74 (4):743-8. Epub 2000/10/06.
45. Morris SN, Ryley D. Fertility preservation: nonsurgical and surgical options. Semin Reprod Med. 2011; 29 (2):147-54. Epub 2011/03/26.
46. Scott SM, Schlaff W. Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin's disease. J Pediatr Adolesc Gynecol. 2005; 18 (5):355-7. Epub 2005/10/06.
47. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertility and Sterility. 2009; 91 (3):694-7. Epub 2008 Aug 3.
48. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril. 2008; 89 (1):166-73. Epub 2007/07/03.
49. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Jama. 2011 ; 306 (3):269-76. Epub 2011 /07/21.
50. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et at. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012; 30 (5):533-8. Epub 2012/01/11.
51. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010; 28 (32):4831-41. Epub 2010/05/12.
52. Danforth DR, Arbogast LK, Mroueh J, Kim MH, Kennard EA, Seifer DB, et at. Dimeric inhibin: a direct marker of ovarian aging. Fertil Steril. 1998; 70 (1):119-23. Epub 1998/07/11.
53. Lass A, Skull J, McVeigh E, Margara R, Winston RM. Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotropin for in-vitro fertilization can predict poor response. Hum Reprod. 1997; 12 (2):294- 7. Epub 1997/02/01.
54. Cohen HL, Shapiro MA, Mandel FS, Shapiro ML. Normal ovaries in neonates and infants: a sonographic study of 77 patients 1 day to 24 months old. AJR Am J Roentgenol. 1993; 160 (3):583-6. Epub 1993/03/01.
55. Scheffer GJ, Broekmans FJ, Looman CW, Blankenstein M, Fauser BC, teJong FH, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod. 2003; 18 (4):700-6. Epub 2003/03/28.
56. Haning RV, Jr., Austin CW, Kuzma DL, Shapiro SS, Zweibel WJ. Ultrasound evaluation of estrogen monitoring for induction of ovulation with menotropins. Fertil Steril. 1982; 37 (5):627-32. Epub 1982/05/01.
57. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril. 2007; 87 (4):764-75. Epub 2007/01/24.
58. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004; 10 (2):77-83. Epub 2004/01/27.
59. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010; 93 (3):855-64. Epub 2008/12/03.
60. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Mullerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012; 27 (3):631-6. Epub 2012/01/13.
61. Josso N, Picard JY, Tran D. The anti-Mullerian hormone. Birth defects original article series. 1977; 13 (2):59-84. Epub 1977/01/01.
62. Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999; 84 (10):3836-44. Epub 1999/10/16.
63. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001; 142 (11):4891-9. Epub 2001/10/19.
64. La Marca A, Sighinolfi G, Radi D, Argento C, Baratdi E, Artenisio AC, et al. Anti-Mutlerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16 (2):113-30. Epub 2009/10/02.
65. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006; 91 (10):4057-63. Epub 2006/06/29.
66. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006; 21 (12):3103-7. Epub 2006/08/23.
67. Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, Cteemann L, et at. Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010; 95 (11):5003-10. Epub 2010/08/20.
68. Ketsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PloS one. 2011 ; 6 (7):e22024. Epub 2011/07/27.
69. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et at. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for In vitro fertilization. Fertil Steril. 2009; 92 (5): 1586-93. Epub 2008/10/22.